Results 21 to 30 of about 88,713,293 (287)

Tim-3 mediates T cell trogocytosis to limit antitumor immunity

The Journal of Clinical Investigation, 2022
T cell immunoglobulin mucin domain-containing protein 3 (Tim-3) negatively regulates innate and adaptive immunity in cancer. To identify the mechanisms of Tim-3 in cancer immunity, we evaluated the effects of Tim-3 blockade in human and mouse melanoma ...
Ornella Pagliano, Robert M. Morrison, Joe-Marc Chauvin, Hridesh Banerjee, Diwakar Davar, Quanquan Ding, Tokiyoshi Tanegashima, Wentao Gao, Saranya R. Chakka, Richelle DeBlasio, Ava Lowin, Kevin Kara, Mignane Ka, Bochra Zidi, Rada Amin, Itay Raphael, Shuowen Zhang, Simon C. Watkins, Cindy Sander, John M. Kirkwood, Marcus Bosenberg, Ana C. Anderson, Vijay K. Kuchroo, Lawrence P. Kane, Alan J. Korman, Arvind Rajpal, Sean M. West, Minhua Han, Christine Bee, Xiaodi Deng, Xiao Min Schebye, Pavel Strop, Hassane M. Zarour   +32 more
doaj   +1 more source

TIM-3 in Leukemia; Immune Response and Beyond

Frontiers in Oncology, 2021
T cell immunoglobulin and mucin domain 3 (TIM-3) expression on malignant cells has been reported in some leukemias. In myelodysplastic syndrome (MDS), increased TIM-3 expression on TH1 cells, regulatory T cells, CD8+ T cells, and hematopoietic stem cells
Mahnaz Rezaei, Jiaxiong Tan, Chengwu Zeng, Yangqiu Li, Mazdak Ganjalikhani-Hakemi, Mazdak Ganjalikhani-Hakemi   +5 more
doaj   +1 more source

Dok-3 deficient mice display different immune clustering and Tim-3 expression

European Journal of Medical Research, 2019
Background Dok-3 has been shown to play an important role in immune system. Tim-3 also has been recognized as an important immune regulator which involves in many diseases. The relationship of them is still unclear.
Wenjiang Yan, Yijia Tian, Peng Sun, Jingjing Yang, Na Li, Yuanyuan Sun, Shuangxi Wang, Cheng Zhang   +7 more
doaj   +1 more source

Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3+ CD8+ T Cells and Survival in Diffuse Large B Cell Lymphoma

Journal of Immunology Research, 2020
Tim-3 is a promising target for antitumor immunotherapy. A number of clinical trials are evaluating the efficacy of anti-Tim-3 therapies as a single agent or combinations in solid tumors and haematologic malignancies.
Tingting Zhang, Tianyuan Ren, Zheng Song, Jing Zhao, Lei Jiao, Zhenzhen Zhang, Jin He, Xianming Liu, Lihua Qiu, Lanfang Li, Shiyong Zhou, Bin Meng, Qiongli Zhai, Xiubao Ren, Zhengzi Qian, Xianhuo Wang, Huilai Zhang   +16 more
doaj   +1 more source

Association of TIM-3 expression with glucose metabolism in Jurkat T cells

BMC Immunology, 2020
Background T cell activation is associated with increase in glycolysis and glutaminolysis. T cell immunoglobulin and mucin domain containing protein-3 (TIM-3), a T cell surface molecule, downregulates T cell activation and leads to insufficient immunity ...
Mi Jin Lee, Su Jin Yun, Bokyoung Lee, Eun Jeong, Gyesoon Yoon, Kyongmin Kim, Sun Park   +6 more
doaj   +1 more source

TIM-3 does not act as a receptor for galectin-9. [PDF]

PLoS Pathogens, 2013
T cell immunoglobulin and mucin protein 3 (TIM-3) is a type I cell surface protein that was originally identified as a marker for murine T helper type 1 cells. TIM-3 was found to negatively regulate murine T cell responses and galectin-9 was described as
Judith Leitner, Armin Rieger, Winfried F Pickl, Gerhard Zlabinger, Katharina Grabmeier-Pfistershammer, Peter Steinberger   +5 more
doaj   +1 more source

Inhibition of melanoma cell-intrinsic Tim-3 stimulates MAPK-dependent tumorigenesis. [PDF]

, 2022
T-cell immunoglobulin and mucin domain 3 (Tim-3) is an immune checkpoint receptor that dampens effector functions and causes terminal exhaustion of cytotoxic T-cells.
Itoh, Yuta, Heppt, Markus V, Lian, Christine G, Silva, Mariana, Murphy, George F, Dimitroff, Charles J, Singh, Praveen, Brandenburg, Anne, Mihm, Martin C, Ramsey, Matthew R, Rasbach, Erik, Geddes-Sweeney, Jenna, Schatton, Tobias, Mucciarone, Kyla N, Stewart, Kate, Liang, Jennifer, Landsberg, Jennifer, Schlapbach, Christoph, Barthel, Steven R, Martins, Christina, Kupper, Thomas S   +20 more
core   +2 more sources

TIM-3 pathway dysregulation and targeting in cancer [PDF]

Expert Review of Anticancer Therapy, 2021
Dysfunction of the immune system is a hallmark of cancer. Through increased understanding of the complex interactions between immunity and cancer, immunotherapy has emerged as a treatment modality for different types of cancer. Promising activity with immunotherapy has been reported in numerous malignancies, but challenges such as limited response ...
Amer M, Zeidan, Rami S, Komrokji, Andrew M, Brunner   +2 more
openaire   +2 more sources

QUANTITATIVE EXPRESSION FEATURES OF PD-1 AND TIM-3 CHECKPOINT MOLECULE RECEPTORS ON CD4⁺ AND CD8⁺ T-CELLS IN BREAST CANCER OF VARYING PROGRESSION DEGREES

Медицинская иммунология, 2021
During the course of chronic viral infections or tumor growth, due to the constant presence of antigen and inflammation, a dysfunctional state of T-cells called exhaustion occurs.
Yu. A. Shevchenko, M. S. Kuznetsova, Yu. N. Khantakova, I. A. Obleukhova, A. A. Khristin, S. V. Sidorov, S. V. Sennikov   +6 more
doaj   +1 more source

10XTYPES Vol.3

Typeface archive book featuring ten typefaces design by Tim Hutchinson. Each typeface is displayed as a full specimen throughout the book plus some experimental & live application of selected typefaces at the end of the ...
Hutchinson, Tim
core   +4 more sources